02:36:31 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-15 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-04-20 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-20 Årsstämma 2022
2022-04-07 Ordinarie utdelning TRVX 0.00 NOK
2022-02-17 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-03-18 Ordinarie utdelning TRVX 0.00 NOK
2021-03-17 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-07 Kvartalsrapport 2020-Q1
2020-04-30 Ordinarie utdelning TRVX 0.00 NOK
2020-04-29 Årsstämma 2020
2020-03-11 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-04-10 Ordinarie utdelning TRVX 0.00 NOK
2019-04-09 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-01 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-03 Kvartalsrapport 2018-Q1
2018-04-12 Ordinarie utdelning TRVX 0.00 NOK
2018-04-11 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-05 Årsstämma 2017
2017-02-16 Bokslutskommuniké 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-14 Ordinarie utdelning TRVX 0.00 NOK
2016-04-13 Årsstämma 2016
2015-06-23 Ordinarie utdelning TRVX 0.00 NOK
2015-06-22 Årsstämma 2015

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Targovax är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs idag under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Oslo.
2022-05-31 14:17:18
Oslo, 31 May 2022: The board of directors of Targovax ASA (OSE:TRVX) ("Targovax"
or the "Company") has resolved to increase the share capital of the Company
following the completion of a an exercise period for vested share options under
the Company's long-term incentive program for employees and the completion of
settlement period for vested restricted stock units ("RSUs"). The settlement
period commenced on 16 May 2022 at 10:00 hours (CEST) and ended on 31 May 2022
at 10:00 hours (CEST).

1. Exercise of options

In total, 4,502 options, each with a subscription price of NOK 0.51 per share
were exercised, giving the option holder the right to subscribe for 4,502 new
shares in total, each with a par value of NOK 0.10.

2. Settlement of RSUs

The board members Diane Mellett and Eva-Lotta Allan have settled 6,049 and
40,811 RSUs, respectively. Hence in total, 46,860 RSUs were settled, giving the
RSUs holders the right to subscribe for 46,860 new shares in total, each with a
par value of NOK 0.10, at a subscription price of NOK 0.10 per share.

The RSU holders have previously elected to receive the RSUs as part of their
board remuneration instead of cash payment pursuant to resolutions by the annual
general meeting (the "AGM") of the Company. The number of RSUs granted was
calculated as the NOK amount of the RSU selected portion of the total
remuneration to the respective board member, divided by the market price for the
shares, calculated as the volume weighted average share price for the 10 trading
days prior to the relevant AGM, being NOK 14.33 per share in 2018, NOK 6.34 per
share in 2019, NOK 6.81 per share in 2020 and NOK 8.80 per share in 2021.

3. Resolution to increase the share capital in Targovax ASA

The board of directors of the Company has today, on 31 May 2022, in accordance
with the authorisation granted by the general meeting on 20 April 2022, resolved
to :

· to increase the share capital with NOK 450.20 by the issuance of 4,502 new
shares, each with a par value of NOK 0.10 in order to facilitate the exercise of
options